000112041 001__ 112041
000112041 005__ 20230519145550.0
000112041 0247_ $$2doi$$a10.1016/j.schres.2021.07.017
000112041 0248_ $$2sideral$$a126547
000112041 037__ $$aART-2021-126547
000112041 041__ $$aeng
000112041 100__ $$aGonzález-Blanco L.
000112041 245__ $$aImpact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis
000112041 260__ $$c2021
000112041 5060_ $$aAccess copy available to the general public$$fUnrestricted
000112041 5203_ $$aObjective: There is high prevalence of cigarette smoking in individuals with first-episode psychosis (FEP) prior to psychosis onset. The purpose of the study was to determine the impact of previous tobacco use with or without cannabis on first psychotic experiences in FEP and the impact of this use on age of onset of symptoms, including prodromes. Methods: Retrospective analyses from the naturalistic, longitudinal, multicentre, “Phenotype-Genotype and Environmental Interaction. Application of a Predictive Model in First Psychotic Episodes (PEPs)” Study. The authors analysed sociodemographic/clinical data of 284 FEP patients and 231 matched healthy controls, and evaluated first psychotic experiences of patients using the Symptom Onset in Schizophrenia Inventory. Results: FEP patients had significantly higher prevalence of tobacco, cannabis, and cocaine use than controls. The FEP group with tobacco use only prior to onset (N = 56) had more sleep disturbances (42.9% vs 18.8%, P = 0.003) and lower prevalence of negative symptoms, specifically social withdrawal (33.9% vs 58%, P = 0.007) than FEP with no substance use (N = 70), as well as lower prevalence of ideas of reference (80.4% vs 92.4%, P = 0.015), perceptual abnormalities (46.4% vs 67.4%, P = 0.006), hallucinations (55.4% vs 71.5%, P = 0.029), and disorganised thinking (41.1% vs 61.1%, P = 0.010) than FEP group with previous tobacco and cannabis use (N = 144). FEP patients with cannabis and tobacco use had lower age at first prodromal or psychotic symptom (mean = 23.73 years [SD = 5.09]) versus those with tobacco use only (mean = 26.21 [SD = 4.80]) (P = 0.011). Conclusions: The use of tobacco alone was not related to earlier age of onset of a first psychotic experience, but the clinical profile of FEP patients is different depending on previous tobacco use with or without cannabis. © 2021 The Authors
000112041 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000112041 590__ $$a4.662$$b2021
000112041 592__ $$a1.451$$b2021
000112041 594__ $$a8.0$$b2021
000112041 591__ $$aPSYCHIATRY$$b64 / 157 = 0.408$$c2021$$dQ2$$eT2
000112041 593__ $$aPsychiatry and Mental Health$$c2021$$dQ1
000112041 591__ $$aPSYCHIATRY$$b47 / 144 = 0.326$$c2021$$dQ2$$eT1
000112041 593__ $$aBiological Psychiatry$$c2021$$dQ1
000112041 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000112041 700__ $$aGarcía-Portilla M.P.
000112041 700__ $$aGutiérrez M.
000112041 700__ $$aMezquida G.
000112041 700__ $$aCuesta M.J.
000112041 700__ $$aUrbiola E.
000112041 700__ $$aAmoretti S.
000112041 700__ $$aBarcones F.$$uUniversidad de Zaragoza
000112041 700__ $$aGonzález-Pinto A.
000112041 700__ $$aPina-Camacho L.
000112041 700__ $$aCorripio I.
000112041 700__ $$aVieta E.
000112041 700__ $$aBaeza I.
000112041 700__ $$aToll A.
000112041 700__ $$aSáiz P.A.
000112041 700__ $$aBobes J.
000112041 700__ $$aBernardo M.
000112041 700__ $$aBioque M.
000112041 700__ $$aSagué M.
000112041 700__ $$aAlonso-Solís A.
000112041 700__ $$aGrasa E.
000112041 700__ $$aGonzález-Ortega I.
000112041 700__ $$aZorrilla I.
000112041 700__ $$0(orcid)0000-0002-7297-6104$$aSantabárbara J.$$uUniversidad de Zaragoza
000112041 700__ $$0(orcid)0000-0003-2284-7862$$aDe-la-Cámara C.$$uUniversidad de Zaragoza
000112041 700__ $$aAguilar E.J.
000112041 700__ $$aNacher J.
000112041 700__ $$aBergé D.
000112041 700__ $$aMané A.
000112041 700__ $$aMontejo L.
000112041 700__ $$aAnmella G.
000112041 700__ $$aCastro-Fornieles J.
000112041 700__ $$ade la Serna E.
000112041 700__ $$aContreras F.
000112041 700__ $$aSáiz-Masvidal C.
000112041 700__ $$aGarcía-Álvarez L.
000112041 700__ $$aBobes-Bascarán T.
000112041 700__ $$aZabala-Rabadán A.
000112041 700__ $$aSegarra-Echevarría R.
000112041 700__ $$aSanchez-Pastor L.
000112041 700__ $$aRodriguez-Jimenez R.
000112041 700__ $$aUsall J.
000112041 700__ $$aButjosa A.
000112041 700__ $$aSarró S.
000112041 700__ $$aGuerrero-Pedraza A.
000112041 700__ $$aIbañez Á.
000112041 700__ $$aRibeiro M.
000112041 700__ $$aBalanzá-Martínez V.
000112041 700__ $$aPEPs Group
000112041 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría
000112041 7102_ $$11011$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Medic.Prevent.Salud Públ.
000112041 773__ $$g236 (2021), 19-28$$pSchizophr. res.$$tSCHIZOPHRENIA RESEARCH$$x0920-9964
000112041 8564_ $$s2542733$$uhttps://zaguan.unizar.es/record/112041/files/texto_completo.pdf$$yVersión publicada
000112041 8564_ $$s2491105$$uhttps://zaguan.unizar.es/record/112041/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000112041 909CO $$ooai:zaguan.unizar.es:112041$$particulos$$pdriver
000112041 951__ $$a2023-05-18-15:48:57
000112041 980__ $$aARTICLE